Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reactive psychological problems that are often hard to distinguish from the `organic' causation of psychopathology. In any event, psychiatric comorbidity in MS deserves greater clinical attention than has been previously paid, because the presence of psychopathology may have deleterious effects on the disease process and impair coping with disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folkman, S., & Moskowitz, J. T. (2004) · Annual Review of Psychology · doi:10.1146/annurev.psych.55.090902.141456 · Cited by 3,485 · cited 1×
“The research findings on coping with MS closely resemble those on coping with stress – that is, positive adjustment is typically associated with problem focused coping and higher symptom levels are associated with emotion-focused coping or escape avoidance [Folkman and Moskowitz, 2004].”
BackgroundCytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365 · cited 1×
“In healthy humans an induced cytokine production was also transiently accompanied with depressed mood, anxiety, and memory impairments [Reichenberg et al. 2001].”
BackgroundDepression in multiple sclerosis: a review
Siegert, R. J. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054635 · Cited by 718 · cited 5×
“However, with the high prevalence rates for depression in MS noted above, it is difficult to draw any meaningful conclusions from anecdotal accounts or individual case reports [Siegert and Abernethy, 2005].”
BackgroundInfluentialCytokine-induced sickness behavior
Kelley, K. W., Bluthé, R.-M., Dantzer, R., Zhou, J.-H., Shen, W.-H., Johnson, R. W., & Broussard, S. R. (2003) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00077-6 · Cited by 716
Chwastiak, L., Ehde, D. M., Gibbons, L. E., Sullivan, M., Bowen, J. D., & Kraft, G. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1862 · Cited by 555
Quality of life in patients with multiple sclerosis
Janardhan, V., & Bakshi, R. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00312-x · Cited by 489 · cited 1×
“It is still not known whether fatigue occurs as a direct result of brain lesions or as a psychological reaction [Janardhan and Bakshi, 2002].”
BackgroundCytokines as mediators of depression: what can we learn from animal studies?
Dunn, A. J., Swiergiel, A. H., & Beaurepaire, R. D. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.023 · Cited by 459
Anxiety disorders and their clinical correlates in multiple sclerosis patients
Korostil, M., & Feinstein, A. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071161 · Cited by 424 · cited 2×
“Female gender, a comorbid diagnosis of depression, and restricted social support were considered as risk factors, but the diagnosis of anxiety disorders had been overlooked and therefore not been treated in most subjects [Korostil and Feinstein, 2007].”
BackgroundCause of death in patients attending multiple sclerosis clinics
Sadovnick, A. D., Eisen, K., Ebers, G. C., & Paty, D. W. (1991) · Neurology · doi:10.1212/wnl.41.8.1193 · Cited by 401 · cited 2×
“In a follow-up study over 16 years, suicide accounted for 15%of all ascertained deaths in patients with MS [Sadovnick et al. 1991].”
BackgroundInfluentialThe Goldman Consensus statement on depression in multiple sclerosis
Goldman Consensus Group (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1162oa · Cited by 329
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., Moreau, T., Pelletier, J., Lubetzki, C., Clanet, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000158272.27070.6a · Cited by 318 · cited 1×
“Modafinil has 1-adrenergic properties and has been studied in two trials with controversial results [Stankoff et al. 2005; Rammohan et al. 2002].”
ResultPro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy
Sutcigil, L., Oktenli, C., Musabak, U., Bozkurt, A., Cansever, A., Uzun, O., Sanisoglu, S. Y., Yesilova, Z., Ozmenler, N., Ozsahin, A., et al. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/76396 · Cited by 315 · cited 1×
“Recently, there was some evidence in the literature suggesting that antidepressants could reduce the release of proinflammatory cytokines and other immunological factors, although their precise neuroimmune mechanisms are little known and remain uncertain [Sutcigil et al. 2007; Leonard, 2001].”
BackgroundJanssens, A. C. J. W., van Doorn, P. A., de Boer, J. B., van der Meché, F. G. A., Passchier, J., & Hintzen, R. Q. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2003.00166.x · Cited by 294
Structural brain abnormalities in multiple sclerosis patients with major depression
Feinstein, A., Roy, P., Lobaugh, N., Feinstein, K., O’Connor, P., & Black, S. (2004) · Neurology · doi:10.1212/01.wnl.0000110316.12086.0c · Cited by 294 · cited 3×
“Here depressive symptoms were associated with lesions in the arcuate fasciculus, medial orbitofrontal regions and limbic perfusion [Feinstein et al. 2004] and in the right hemisphere with frontal lesion load and temporal brain volume [Zorzon et al.”
BackgroundInfluentialA Randomized Controlled Trial of Cognitive Behavior Therapy for Multiple Sclerosis Fatigue
van Kessel, K., Moss-Morris, R., Willoughby, E., Chalder, T., Johnson, M. H., & Robinson, E. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181643065 · Cited by 276 · cited 1×
“Even 6 months after treatment, both treatment groups reported levels of fatigue equivalent to those of the healthy comparison group [van Kessel et al. 2008].”
ResultPsychological interventions for multiple sclerosis.
Thomas, P. W., Thomas, S., Hillier, C., Galvin, K., & Baker, R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004431.pub2 · Cited by 271
Depression and anxiety amongst multiple sclerosis patients
Beiske, A. G., Svensson, E., Sandanger, I., Czujko, B., Pedersen, E. D., Aarseth, J. H., & Myhr, K. M. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02041.x · Cited by 257
Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects
Zorzon, M., de Masi, R., Nasuelli, D., Ukmar, M., Pozzi Mucelli, R., Cazzato, G., Bratina, A., & Zivadinov, R. (2001) · Journal of Neurology · doi:10.1007/s004150170184 · Cited by 249
Psychological aspects of multiple sclerosis
Sá, M. J. (2008) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2007.10.001 · Cited by 155
Treatment of depression in multiple sclerosis: Review and meta-analysis.
Mohr, D. C., & Goodkin, D. E. (1999) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.6.1.1 · Cited by 155
An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis
Larcombe, N. A., & Wilson, P. H. (1984) · British Journal of Psychiatry · doi:10.1192/bjp.145.4.366 · Cited by 118
Janssens, A. C., Buljevac, D., van Doorn, P. A., van der Meché, F. G., Polman, C. H., Passchier, J., & Hintzen, R. Q. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070935 · Cited by 107 · cited 1×
“Like depression, anxiety seems to be associated with disease activity but not with its duration or severity [Janssens et al. 2006].”
BackgroundThe EAE-associated behavioral syndrome II. Modulation by anti-inflammatory treatments
Pollak, Y. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00073-0 · Cited by 56 · cited 1×
“In accordance with a cytokinemediated pathogenesis of these symptoms, the onset of sickness behaviour coincided with inflammatory cell infiltration of the brain as well as cytokine synthesis in brain tissue and anti-inflammatory treatment ameliorated the behavioural effects [Pollak et al. 2003].”
BackgroundPsychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans
Reiss, J. P., Sam, D., & Sareen, J. (2006) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2005.02.017 · Cited by 31
Cited by
Microbiome, inflammation, epigenetic alterations, and mental diseases
Alam, R., Abdolmaleky, H. M., & Zhou, J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32567 · Cited by 240
The prevalence of anxiety and associated factors in persons with multiple sclerosis
Pham, T., Jetté, N., Bulloch, A. G. M., Burton, J. M., Wiebe, S., & Patten, S. B. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.11.003 · Cited by 64
Heffer-Rahn, P., & Fisher, P. L. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.11.014 · Cited by 22
Saul, A., Taylor, B., Simpson, S., Ponsonby, A.-L., Blizzard, L., Dwyer, T., McMorran, B., Wood, B., & van der Mei, I. A. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518770021 · Cited by 9
Metadata
- Authors
- Haussleiter, I. S., Brüne, M., & Juckel, G.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2009-01
- Volume
- 2
- Issue
- 1
- Pages
- 13-29
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W2112843710
- Cited by
- 93
- References
- 24
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.